BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...
Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is ...
Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...
Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
Stocktwits on MSN20h
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment JumpsAclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback